Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 18, 2005Journal of Clinical OncologyOpen Access

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMatthew P. GoetzMayo ClinicDTDavid O. ToftNorthwestern UniversityJRJoel M. ReidMayo Clinic

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Goetz et al. (2005) studied this question.

synapsesocial.com/papers/6a7031dcf44fa9f079ddc2a6https://doi.org/10.1200/jco.2005.09.119
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers2005 · 194 citations
  2. 2Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies2005 · 491 citations
  3. 3Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway1998 · 99 citations
  4. 4Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp901996 · 409 citations